The management and reimbursement of inpatient drug costs in Medicaid programs are pivotal topics, especially with the proliferation of high-cost therapies. The emergence of expensive inpatient drugs, such as cell and gene therapies, have challenged Diagnosis Related Groups (DRGs), the traditional bundled payment system used by hospitals.

Will the involvement of a federal agency change the progress of value-based purchasing in the Medicaid program? The 2024 calendar year will provide insight into whether this intervention will expand opportunities for states and manufacturers.

Artia Solutions and The Garner Group are proud to support the recognition of February 15, 2024, as Angelman Syndrome Awareness Day in the state of Florida through SR 1802, sponsored by Senator Alexis Calatayud, R-Miami Dade.

Who will have the happier new year in 2024 – pharmaceutical manufacturers or state Medicaid programs? See what considerations will be made by each side over the next six-to-eight months to preserve finances while serving Medicaid recipients.

More than 530 attendees gathered at the downtown JW Marriott in Nashville, Tennessee, on June 12-14, 2023, for the third Crossroads: An Artia Solutions Conference.

Manufacturers are often intimidated when directed by New York to participate in Medicaid, due to the uniqueness of their programs. We aim to eliminate confusion in navigating these processes to resolution.